Latest News

Dr David M. Cutler Highlights the Importance of Reauthorizing the CHIP Program
Every 5 years, the Children's Health Insurance Program (CHIP) has to be reauthorized. This year the program has to be reauthorized by September, and that normally would have happened by now, except the issue has flown under the radar with the other big healthcare issues dominating Congress' attention, explained David. M. Cutler, PhD, of Harvard University.
Stakeholders’ perspectives can vary, and their different preferences matter when it comes to value assessment, but only if the right questions are being asked.
Dr Gail Wilensky: Senate Health Bill Will Be to the Left of the House
While there is a lot of uncertainty about what the final Senate healthcare reform bill will look like, Gail Wilensky, PhD, of Project HOPE, expects the bill will ultimately be to the left of the House bill in order to get the moderates on board.
A panel at the Pharmacy Quality Alliance talks about how to take patient input and turn it into meaningful measurement.
Healthcare is a complicated issue with few, if any, easy fixes. The important thing is that the country continues to move forward, according to panelists during the first plenary at the ISPOR 22nd Annual International Meeting, held May 20-24 in Boston, Massachusetts.
Comprehensive genetic testing using multigene testing panels for prostate cancer can arm genetic counselors with the information they need to guide precision therapy, even in men with early stage disease but a strong family history of the disease.
The findings come after other data recently showed an overall increase in diabetes incidence among youth, especially minorities.
Although each individual rare cancer affects a small percentage of patients, the collective group of 181 rare cancers is responsible for significant disease burden in the United States.
The proposed budget reportedly includes the $880 billion cut to Medicaid over 10 years that is part of the American Health Care Act. Elsewhere today, the Trump administration is expected to file for a 90-day delay in a lawsuit that could ultimately end subsidies for those buying insurance on the exchanges.
Dr Aimee Tharaldson Discusses the Orphan Drug Approval Trend
About 40% of new specialty drugs in 2017 are expected to be for orphan drug indications, which is keeping with the trend; however, an upcoming investigation into potential abuses of the Orphan Drug Act could have an unknown impact on development and prices, said Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts.
Most contracts now have penalties for not reaching targets, and adherence remains a challenge.
Dr Gail Bridges on the Importance of Real-World Results Matching Clinical Trial Outcomes
With the high cost of new drugs to cure hepatitis C, ensuring that real-world outcomes are consistent with those seen in clinical trials is important, explained Gail Bridges, PharmD, of Accredo Health. She explained that Accredo ensured patients adhered to hepatitis C drugs in order to get the best outcomes through a disease- and drug-specific education program.
Podcast: This Week in Managed Care—Hint of Medicare Drug Rebates, and Other News
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

From the Journals

Across many measures of Veterans Health Administration mental health care program characteristics, treatment continuity is most strongly and positively associated with patient satisfaction.  
This study investigates the impact of state prescription drug monitoring programs on drug overdose mortality rates for all drug categories.
This study utilizes a validated instrument to create case and control groups to measure the effect of the Veterans Health Administration (VHA)’s patient-centered medical home (PCMH) model on utilization patterns among veterans with posttraumatic stress disorder (PTSD).
This study highlights disparities in care for diabetes and hypertension for individuals with serious mental illness compared with the general Medicaid and Medicare populations.
An interview with Daryl Pritchard, PhD, vice president for Science Policy at the Personalized Medicine Coalition, on the FDA's drug approval process, developments in the personalized medicine field, and reimbursement models that integrate diagnostics.
This study identified populations with non-cancer chronic pain to determine which patients may be more likely to receive an opioid prescription in an outpatient setting.
An overview of the FDA's Oncology Center of Excellence—a collaborative approach to the clinical approval process.
At the The American Journal of Managed Care®'s Spring 2017 Oncology Stakeholders Summit, the discussion touched off-label communication, the evolving clinical trial design, and healthcare reform, all while ensuring care is patient-centered.
The Institute for Clinical and Economic Review (ICER), has established a robust health technology assessment strategy for engaging patients so that the entire process is informed by the patient experience and what “value” means to them.
Compendia
COPD Compendium
Diabetes Compendium
GI Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Know Your News
HF Compendium
Formulary
Upcoming Partner Events
June 15-16, 2017
Philadelphia, PA
August 16-17, 2017
Philadelphia, PA
October 24-25, 2017
San Francisco, CA
Managed Care Cast
Managed Care Cast

Most Popular

AJMC Strategic Alliance

$vacMongoViewPlus$